Could a simple blood test predict dangerous pregnancy complication?
NCT ID NCT07411937
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will measure a substance called kynurenine in the blood of 204 pregnant women, some with chronic kidney disease and some without. The goal is to see if kynurenine levels are linked to preeclampsia, a serious condition that can harm both mother and baby. Researchers hope this will lead to better ways to predict and prevent preeclampsia in the future.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help identify a biomarker to predict preeclampsia in pregnant women with kidney disease.
- What could go wrong
- This is an observational study, not a treatment trial. It may not lead to any direct medical benefit or change in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 204 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Mar 2026
An estimate. Start dates often move.
- Expected to finish
-
May 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adult pregnant women \<14 weeks of amenorrhea * With or without CKD stage 2-4 (eGFR 15-89 mL/min/1.73m², diagnosed before pregnancy) * Written informed consent * Affiliation to a social security system Exclusion Criteria: * Multiple pregnancy * Kidney transplantation * Persons under guardianship or legal protection
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic kidney diseases are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Marie MULLER
Reims, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a nurse and a neighbor help tame chronic disease?
- Which SGLT2 inhibitor wins? trial pits empagliflozin against dapagliflozin
- How much lidocaine reaches a newborn during an urgent C-Section?
- Could pregnant patients skip clinic visits and monitor their baby from home?
- Does better dialysis keep parathyroid hormone in check?
- Biobank aims to unlock the mysteries of calciphylaxis